These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17375031)

  • 1. Pramipexole (Mirapex) for restless legs syndrome.
    Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
    [No Abstract]   [Full Text] [Related]  

  • 2. Pramipexole: new indication. Restless legs: still no satisfactory drug treatment.
    Prescrire Int; 2007 Feb; 16(87):12. PubMed ID: 17323517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with pramipexole in the treatment of restless legs syndrome.
    Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
    Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
    Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
    Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
    Montagna P; Hornyak M; Ulfberg J; Hong SB; Koester J; Crespi G; Albrecht S
    Sleep Med; 2011 Jan; 12(1):34-40. PubMed ID: 20965780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
    Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
    J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials.
    Hornyak M; Sohr M; Busse M;
    Sleep Med; 2011 Feb; 12(2):186-9. PubMed ID: 21256799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
    Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
    Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
    Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
    Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial.
    Ma JF; Wan Q; Hu XY; Sun SG; Wang WZ; Zhao ZX; Wang YJ; Liu CF; Li JM; Jiang YP; Chen SD
    Sleep Med; 2012 Jan; 13(1):58-63. PubMed ID: 22137119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
    Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
    J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
    Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
    Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of cluster headache with pramipexole.
    Ossemann M
    Acta Neurol Belg; 2010 Sep; 110(3):279-80. PubMed ID: 21114140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep.
    Manconi M; Ferri R; Zucconi M; Clemens S; Rundo F; Oldani A; Ferini-Strambi L
    Sleep Med; 2011 Jan; 12(1):47-55. PubMed ID: 20851046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness.
    Kallweit U; Khatami R; Pizza F; Mathis J; Bassetti CL
    Clin Neuropharmacol; 2010; 33(6):276-8. PubMed ID: 21060282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole: in restless legs syndrome.
    McCormack PL; Siddiqui MA
    CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impulse control disorder induced by the use of dopamine agonists].
    Weber WE; Nijssen PC
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):80-1. PubMed ID: 19235343
    [No Abstract]   [Full Text] [Related]  

  • 19. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
    Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
    Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome.
    Högl B; Garcia-Borreguero D; Trenkwalder C; Ferini-Strambi L; Hening W; Poewe W; Brenner SS; Fraessdorf M; Busse M; Albrecht S; Allen RP
    Sleep Med; 2011 Apr; 12(4):351-60. PubMed ID: 21354368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.